| 1 |
34074804 | Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations. | 2022 Jan 1 |
1 |
| 2 |
35007861 | Potential applications of clickable probes in EGFR activity visualization and prediction of EGFR-TKI therapy response for NSCLC patients. | 2022 Feb 15 |
2 |
| 3 |
35081479 | Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy. | 2022 Mar |
1 |
| 4 |
35105467 | [Drug-drug interactions of tyrosine kinase inhibitors in treatment of non-small-cell lung carcinoma]. | 2022 Mar |
1 |
| 5 |
35195881 | The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib. | 2022 Mar |
2 |
| 6 |
35305596 | Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study). | 2022 Mar 19 |
2 |
| 7 |
35343086 | Bevacizumab plus dacomitinib combination therapy for L858R-mutated metastatic lung adenocarcinoma: A report of two cases. | 2022 May |
1 |
| 8 |
35415873 | Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02). | 2022 May |
5 |
| 9 |
35462930 | Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports. | 2022 |
1 |
| 10 |
35626421 | Utility of Next-Generation Sequencing in the Reconstruction of Clonal Architecture in a Patient with an EGFR Mutated Advanced Non-Small Cell Lung Cancer: A Case Report. | 2022 May 19 |
3 |
| 11 |
32959703 | Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a Japanese population. | 2021 Jan |
1 |
| 12 |
33112047 | Remarkable response to dacomitinib in a patient with leptomeningeal carcinomatosis due to EGFR-mutant non-small cell lung cancer. | 2021 Jan |
9 |
| 13 |
33153414 | EGFR tyrosine kinase inhibitors in non-small cell lung cancer: treatment paradigm, current evidence, and challenges. | 2021 Oct |
1 |
| 14 |
33251343 | Dacomitinib and gedatolisib in combination with fractionated radiation in head and neck cancer. | 2021 Jan |
1 |
| 15 |
33331989 | Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. | 2021 Feb |
1 |
| 16 |
33333327 | Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. | 2021 May |
2 |
| 17 |
33352385 | Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report. | 2021 Feb |
6 |
| 18 |
33635095 | Dacomitinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis. | 2021 Mar |
1 |
| 19 |
33651475 | Dacomitinib as a retreatment for advanced non-small cell lung cancer patient with an uncommon EGFR mutation. | 2021 Apr |
4 |
| 20 |
33721611 | Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). | 2021 Apr |
1 |
| 21 |
33754924 | The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (EGFRm NSCLC) in Sweden. | 2021 Jan-Dec |
1 |
| 22 |
33937055 | Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment. | 2021 |
1 |
| 23 |
33941614 | Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors. | 2021 Jul 15 |
1 |
| 24 |
34093040 | Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer. | 2021 |
2 |
| 25 |
34113397 | Dacomitinib improves chemosensitivity of cisplatin-resistant human ovarian cancer cells. | 2021 Jul |
3 |
| 26 |
34120312 | Evaluation of the Effect of Proton Pump Inhibitors on the Efficacy of Dacomitinib and Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer and EGFR-Activating Mutations. | 2021 Dec |
3 |
| 27 |
34140482 | Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer. | 2021 Jun 17 |
1 |
| 28 |
34250398 | Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib. | 2021 |
1 |
| 29 |
34268373 | Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line therapy of patients with EGFR mutation-positive non-small-cell lung cancer in the United States and China. | 2021 May |
4 |
| 30 |
34397694 | Successful treatment of 2 patients with brain metastases from non-small cell lung cancer with epidermal growth factor receptor mutation receiving dacomitinib: A case report. | 2021 Jul 30 |
2 |
| 31 |
34564058 | Simultaneous determination of dacomitinib and its major metabolite, O-desmethyl dacomitinib in human plasma by LC-MS/MS and its application to clinical testing in patients with non-small cell lung cancer. | 2021 Oct 1 |
1 |
| 32 |
34602008 | Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer. | 2021 Oct 11 |
1 |
| 33 |
34751504 | Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases. | 2021 Dec |
7 |
| 34 |
34799322 | REPORT- Clinical outcomes of using second - versus first-Generation EGFR-tkis for the First-Line treatment of advanced NSCLC patients with EGFR mutations: A meta-analysis. | 2021 Jul |
1 |
| 35 |
34926262 | Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report. | 2021 |
2 |
| 36 |
34944068 | EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios. | 2021 Dec 17 |
4 |
| 37 |
34970476 | Modelled Economic Analysis for Dacomitinib-A Cost Effectiveness Analysis in Treating Patients With EGFR-Mutation-Positive Non-Small Cell Lung Cancer in China. | 2021 |
3 |
| 38 |
31858327 | Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer. | 2020 Jun |
3 |
| 39 |
31953310 | ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer. | 2020 May 1 |
2 |
| 40 |
32159882 | Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer. | 2020 May |
1 |
| 41 |
32272733 | Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of Dacomitinib. | 2020 Apr 7 |
3 |
| 42 |
32292093 | Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer? | 2020 Aug |
4 |
| 43 |
32296006 | Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib. | 2020 Jul 15 |
4 |
| 44 |
32869649 | Network meta analysis of first-line therapy for advanced EGFR mutation positive non-small-cell lung cancer: updated overall survival. | 2020 Dec |
1 |
| 45 |
32923886 | Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. | 2020 |
2 |
| 46 |
30500458 | Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. | 2019 Jan |
1 |
| 47 |
30612075 | Quantitative bioanalytical assay for the human epidermal growth factor receptor (HER) inhibitor dacomitinib in rat plasma by UPLC-MS/MS. | 2019 Mar 20 |
2 |
| 48 |
30644426 | Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy. | 2019 Jan 15 |
2 |
| 49 |
30839234 | Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis. | 2019 May |
1 |
| 50 |
30863108 | First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis. | 2019 |
3 |